Nexalin Technology Inc [NXL] stock is trading at $0.68, down -2.86%. An important factor to consider is whether the stock is rising or falling in short-term value. The NXL shares have gain 6.92% over the last week, with a monthly amount drifted -16.04%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Nexalin Technology Inc [NXL] stock has fluctuated between $0.25 and $4.05 over the past year. Nexalin Technology Inc [NASDAQ: NXL] shares were valued at $0.68 at the most recent close of the market.
Analyzing the NXL fundamentals
Nexalin Technology Inc [NASDAQ:NXL] reported sales of 0.15M for the trailing twelve months, which represents a drop of -24.48%. Gross Profit Margin for this corporation currently stands at -6.2% with Operating Profit Margin at -42.69%, Pretax Profit Margin comes in at -35.99%, and Net Profit Margin reading is -35.99%. To continue investigating profitability, this company’s Return on Assets is posted at -3.46, Equity is -2.14 and Total Capital is -4.75.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6534 points at the first support level, and at 0.6268 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7033, and for the 2nd resistance point, it is at 0.7266.
Ratios To Look Out For
For context, Nexalin Technology Inc’s Current Ratio is 5.57. On the other hand, the Quick Ratio is 4.89, and the Cash Ratio is 4.0. Considering the valuation of this stock, the price to sales ratio is 48.01, the price to book ratio is 3.82.
Transactions by insiders
Recent insider trading involved Owens David, Chief Medical Officer, that happened on Aug 13 ’24 when 1000.0 shares were purchased. Chief Medical Officer, Owens David completed a deal on Jun 28 ’24 to buy 1000.0 shares. Meanwhile, Chief Medical Officer Owens David bought 1619.0 shares on Jun 18 ’24.
